Current Report Filing (8-k)
28 Abril 2015 - 5:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 22, 2015
PLANDAÍ BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its
charter)
Nevada |
000-51206 |
45-3642179 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1451 North 200 East Suite #130C, Logan UT |
84341 |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant's telephone number, including area
code: (801) 209-1227
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 4 – MATTERS RELATED TO ACCOUNTANTS AND FINANCIALS
STATEMENTS
ITEM 4.01 CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT
(a) On April 22, 2015, the Registrant
accepted the resignation of Terry L. Johnson, CPA (“Johnson”) from his engagement to be the independent certifying
accountant for the Registrant.
Other than an explanatory paragraph included
in Johnson’s audit report for the Registrant's fiscal years ended June 30, 2014 and 2013 relating to the uncertainty
of the Registrant's ability to continue as a going concern, the audit reports of Johnson on the Registrant's financial statements
for the last fiscal year ended June 30, 2014 and 2013 through April 22, 2015, did not contain an adverse opinion or a disclaimer
of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.
During the Registrant's 2014 and 2013
fiscal year and through the date of this Current Report on Form 8-K, (1) there were no disagreements with Johnson on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved
to the satisfaction of Johnson, would have caused Johnson to make reference to the subject matter of the disagreements in connection
with their report, and (2) there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation
S-K.
(b) On April 22, 2015, the Registrant’s Board of Directors approved the engagement of Danielle M. Adams, CPA of Adams Advisory,
LLC (“Adams”), as the Registrant's independent accountant effective immediately to audit the Registrant’s financial
statements and to perform reviews of interim financial statements. During the fiscal years ended June 30, 2014 and 2013 through
April 22, 2015 neither the Registrant nor anyone acting on its behalf consulted with Adams regarding (i) either the application
of any accounting principles to a specific completed or contemplated transaction of the Registrant, or the type of audit opinion
that might be rendered by Adams on the Registrant's financial statements; or (ii) any matter that was either the subject of a
disagreement with Johnson or a reportable event with respect to Johnson.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SECTION 9 – FINANCIAL STATEMENTS
AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit No. |
Document |
Location |
16.1
|
Letter dated April 22, 2015, from Terry L. Johnson, CPA to the Securities and Exchange Commission. |
Filed herewith |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
PLANDAÍ BIOTECHNOLOGY, INC. |
|
|
|
By: /s/ Roger Duffield
Roger Duffield, Chief Executive Officer
|
Date: April 27, 2015
EXHIBIT 16.1
TERRY L. JOHNSON,
CPA
406 Greyford Lane
Casselberry, Florida
32707
Phone 407-721-4753
Fax/Voice Message
866-813-3428
E-mail cpatlj@yahoo.com
April 22, 2015
Office of the Chief Accountant
Securities and Exchange Commission
100F Street, NE
Washington, D.C. 20549
Dear Sir/Madam:
We have read the statements
made by PLANDAÍ BIOTECHNOLOGY, INC., which were provided to us and which we understand will be filed with the
Commission pursuant to Item 4.01 of its Form 8-K, regarding our resignation as their certifying accountant. We agree with the
statements concerning our firm in such Current Report on Form 8-K. We have no basis to agree or disagree with other
statements made under Item 4.01.
We hereby consent to the filing of this letter as
an exhibit to the foregoing report on Form 8-K.
Very truly yours,
/s/ Terry L. Johnson, CPA
Casselberry, Florida
Plandai Biotechnology (PK) (USOTC:PLPL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024